Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine

In 2019, the United States Food and Drug Administration accorded restricted approval to Sanofi Pasteur's Dengvaxia, a live attenuated vaccine (LAV) for dengue fever, a mosquito-borne viral disease, caused by four antigenically distinct dengue virus serotypes (DENV 1-4). The reason for this limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukla, Rahul, Ramasamy, Viswanathan, Shanmugam, Rajgokul K., Ahuja, Richa, Khanna, Navin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642463/
https://www.ncbi.nlm.nih.gov/pubmed/33194810
http://dx.doi.org/10.3389/fcimb.2020.572681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642463/
https://www.ncbi.nlm.nih.gov/pubmed/33194810
http://dx.doi.org/10.3389/fcimb.2020.572681

Ejemplares similares